Friday, February 24, 2012
The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
Feb 2012
Source
Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol and The Laboratory of Integrative Biosciences, College of Life Sciences, Sun Yat-Sen University, Guangzhou 510275, China. gerg@mail.sysu.edu.cn.
Abstract
Helicobacter pylori causes various gastric diseases, such as gastritis, peptic ulcerations and gastric cancer. Bismuth-based triple or quadruple therapies have been commonly recommended for the treatment of H. pylori infections. Up to now, the molecular mechanisms by which bismuth inhibits the growth of H. pylori are far from clear. The present concise review intends to cover the most recent reports and discoveries in the field of the inhibitory mechanism of bismuth against H. pylori as well as the bacterial protective response to drug treatment, which will help us to further understand the molecular mechanisms underlying the actions of metal-based drugs and stimulate further development of effective anti-bacterial drugs.
Labels: anti-bacterial drugs, gastric diseases, gastritis, Helicobacter pylori, peptic ulcerations gastric cancer
# posted by Pat O'Connor @ 7:15 AM
Monday, April 16, 2007
Helicobacter pylori Detection and Antimicrobial Susceptibility Testing.
Helicobacter pylori Detection and Antimicrobial Susceptibility Testing.
Clin Microbiol Rev. 2007 Apr
Megraud F,
Lehours P.
Laboratoire de Bacteriologie, Hopital Pellegrin, Place Amelie Raba-Leon, 33076 Bordeaux cedex, France. francis.megraud@chu-bordeaux.fr.
The discovery of Helicobacter pylori in 1982 was the starting point of a revolution concerning the concepts and management of gastroduodenal diseases. It is now well accepted that the most common stomach disease, peptic ulcer disease, is an infectious disease, and all consensus conferences agree that the causative agent, H. pylori, must be treated with antibiotics. Furthermore, the concept emerged that this bacterium could be the trigger of various malignant diseases of the stomach, and it is now a model for chronic bacterial infections causing cancer. Most of the many different techniques involved in diagnosis of H. pylori infection are performed in clinical microbiology laboratories. The aim of this article is to review the current status of these methods and their application, highlighting the important progress which has been made in the past decade. Both invasive and noninvasive techniques will be reviewed.
Clinical Microbiology Reviews
Clin Microbiol Rev. 2007 Apr
Megraud F,
Lehours P.
Laboratoire de Bacteriologie, Hopital Pellegrin, Place Amelie Raba-Leon, 33076 Bordeaux cedex, France. francis.megraud@chu-bordeaux.fr.
The discovery of Helicobacter pylori in 1982 was the starting point of a revolution concerning the concepts and management of gastroduodenal diseases. It is now well accepted that the most common stomach disease, peptic ulcer disease, is an infectious disease, and all consensus conferences agree that the causative agent, H. pylori, must be treated with antibiotics. Furthermore, the concept emerged that this bacterium could be the trigger of various malignant diseases of the stomach, and it is now a model for chronic bacterial infections causing cancer. Most of the many different techniques involved in diagnosis of H. pylori infection are performed in clinical microbiology laboratories. The aim of this article is to review the current status of these methods and their application, highlighting the important progress which has been made in the past decade. Both invasive and noninvasive techniques will be reviewed.
Clinical Microbiology Reviews
Labels: Helicobacter pylori
# posted by Pat O'Connor @ 4:45 AM
